<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03375775</url>
  </required_header>
  <id_info>
    <org_study_id>DNR 2015/3:8 EPN Stockholm</org_study_id>
    <nct_id>NCT03375775</nct_id>
  </id_info>
  <brief_title>Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children</brief_title>
  <official_title>Evaluation of Clinical and Immunological Parameters in Children Treated With Subcutaneous Immunotherapy Towards Pollen - a Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to prospectively explore associations between immunological parameters in
      blood and clinical effect of subcutaneous immunotherapy (SCIT) in children with severe
      allergy towards pollen. Half of the children will receive SCIT while the other half will
      start SCIT after the study is finished. Clinical evaluations of symptoms and an immunological
      survey will be performed before start of SCIT and after one year of treatment. Some of the
      immunological parameters will also be checked after 6 months of treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before start of SCIT, with Alutard pollenextract/s from &quot; Allergologisk Laboratorium
      Köbenhavn&quot; (ALK), and after one year of treatment, immunoglobulin E (IgE)-antibody levels
      towards the crude allergen and important allergen components in birch and grasspollen
      (timothy) will be measured in blood. While IgE- antibodies are considered to be an indicator
      of allergy IgG- and IgG4-antibodies are considered to be &quot;blocking&quot; antibodies in
      IgE-mediated allergy. Therefore the investigators will measure the IgG- and IgG4-antibody
      levels to crude allergens and applicable allergen components before start, when maintenance
      dose is reached (after 6 months) and after one year of treatment. In order to evaluate
      quality of life, a validated form (DISABKIDS) will be used. Symptom score will be rated by a
      validated form (LILA). The need for medication to treat allergic rhinitis and asthma will be
      assessed using questionnaires. A conjunctival provocation with the applicable allergen(s)
      will be performed before start of SCIT and after one year of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open controlled study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to a Conjunctival Allergen Challenge</measure>
    <time_frame>Before treatment and after 12 months</time_frame>
    <description>Change in the dose of allergen needed to elicit a clinical response following ocular administration of the allergen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PADQLQ (pediatric allergic disease quality of life questionnaire) in Swedish LILA</measure>
    <time_frame>Baseline and after 12 months of immunotherapy</time_frame>
    <description>Includes 26 questions regarding allergic symptoms scored from 0 (no symptoms) to 6 (very severe symptoms) during pollen season. Difference in change of total score between intervention and control group will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire regarding use of pharmacologic treatment for allergy and asthma during pollen season</measure>
    <time_frame>Baseline and after 12 months of immunotherapy</time_frame>
    <description>Frequency of use of 8 different drugs will be scored from 0(never) to 5 (daily). Difference in change of total score between intervention and control group will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire regarding quality of life</measure>
    <time_frame>Baseline and after 12 months of immunotherapy</time_frame>
    <description>DISABKIDS, a european quality of life questionnaire used in children with chronic diseases consisting of 37 quality of life questions with answers rated from ever (0=best) to never (5= worst). Difference in change of total score between intervention and control group will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of IgE-antibodies</measure>
    <time_frame>Baseline and after 12 months of immunotherapy</time_frame>
    <description>Difference in change between intervention and control group will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of IgG-antibodies</measure>
    <time_frame>Baseline and after 12 months of immunotherapy</time_frame>
    <description>Difference in change between intervention and control group will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of IgG4-antibodies</measure>
    <time_frame>Baseline and after 12 months of immunotherapy</time_frame>
    <description>Difference in change between intervention and control group will be assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Rhinitis, Allergic</condition>
  <condition>Conjunctivitis, Allergic</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No immunotherapy, symptomatic treatment These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy</intervention_name>
    <description>According to standardized clinical protocol</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Subcutaneous immunotherapy with grass and/or birch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No immunotherapy, symptomatic treatment</intervention_name>
    <description>These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Seasonal Rhinoconjunctivitis caused by grass and/or birch pollen allergy

          -  Insufficient clinical effect of symptomatic treatment (antihistamine, nasal
             corticosteroids)

          -  IgE antibodies to grass and/or birch pollen antigens

        Exclusion Criteria:

          -  severe comorbidity, severe asthma, pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Ingemansson, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Schmid JM, Würtzen PA, Dahl R, Hoffmann HJ. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract. J Allergy Clin Immunol. 2016 Feb;137(2):562-70. doi: 10.1016/j.jaci.2015.05.023. Epub 2015 Jun 30.</citation>
    <PMID>26141262</PMID>
  </results_reference>
  <results_reference>
    <citation>Borres MP, Ebisawa M, Eigenmann PA. Use of allergen components begins a new era in pediatric allergology. Pediatr Allergy Immunol. 2011 Aug;22(5):454-61. doi: 10.1111/j.1399-3038.2011.01197.x. Review.</citation>
    <PMID>21771081</PMID>
  </results_reference>
  <results_reference>
    <citation>Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, Nelson H, Akdis CA. Update on allergy immunotherapy: American Academy of Allergy, Asthma &amp; Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013 May;131(5):1288-96.e3. doi: 10.1016/j.jaci.2013.01.049. Epub 2013 Mar 14. Review.</citation>
    <PMID>23498595</PMID>
  </results_reference>
  <results_reference>
    <citation>Kiotseridis H, Cilio CM, Bjermer L, Aurivillius M, Jacobsson H, Tunsäter A. Swedish translation and validation of the Pediatric Allergic Disease Quality of Life Questionnaire (PADQLQ). Acta Paediatr. 2011 Feb;100(2):242-7. doi: 10.1111/j.1651-2227.2010.02028.x. Epub 2010 Oct 18.</citation>
    <PMID>20874810</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmidt S, Debensason D, Mühlan H, Petersen C, Power M, Simeoni MC, Bullinger M; European DISABKIDS Group. The DISABKIDS generic quality of life instrument showed cross-cultural validity. J Clin Epidemiol. 2006 Jun;59(6):587-98. Epub 2006 May 2.</citation>
    <PMID>16713521</PMID>
  </results_reference>
  <results_reference>
    <citation>Fauquert JL, Jedrzejczak-Czechowicz M, Rondon C, Calder V, Silva D, Kvenshagen BK, Callebaut I, Allegri P, Santos N, Doan S, Perez Formigo D, Chiambaretta F, Delgado L, Leonardi A; Interest Group on Ocular Allergy (IGOA) from the European Academy of Allergy and Clinical Immunology. Conjunctival allergen provocation test : guidelines for daily practice. Allergy. 2017 Jan;72(1):43-54. doi: 10.1111/all.12986. Epub 2016 Aug 18. Review.</citation>
    <PMID>27430124</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Maria Ingemansson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

